Innovative biotechnology company specializing in new drug discovery and development, Avelos Therapeutics, has received a glowing endorsement from the venture capital community by raising $8 million in the startup's Series A funding round. The funding will support the company's targeted, biomarker-driven onco-therapeutics that aim to target cancerous cells that have long been deemed "undruggable," using the concept of synthetic lethality. Financing was provided by several well-known venture capital firms, including SV Investment, UTC Investment, Quad Investment Management, Timepolio Asset Management, Mirae Asset Venture Investment and Mirae Asset Capital.